Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Gastroenterology news this month spanned oncology,

 approved daraxonrasib (Rasonque), a first-in-class oral RAS inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. The approval was based on phase 3 RASolute 302 data showing a median overall survival of 13.2 months versus 6.7 months with chemotherapy.

, Remo Panaccione, MD, of the University of Calgary discussed phase 3 ABTECT maintenance data showing obefazimod sustained clinical remission through week 44, including in patients who had not initially responded to induction therapy. Abivax is planning an NDA submission in the fourth quarter of 2026.

A reanalysis of Sweden's Stockholm-Gotland screening program, discussed by Johannes Blom, MD, PhD, of the Karolinska Institute, found that correcting for contamination bias and nonadherence raised the estimated mortality reduction from actual participation in colorectal cancer screening to 43%, well above the original 14% estimate.

Elsewhere, Andrew Chan, MD, MPH, of Massachusetts General Hospital discussed a 2-decade cohort study linking sugar-sweetened beverage intake to higher gastric cancer incidence, with no similar association for artificially sweetened beverages. And Elizabeth Spencer, MD, of the Icahn School of Medicine at Mount Sinai discussed new findings tying prenatal exposure to PFAS, or "forever chemicals," to elevated markers of intestinal inflammation in children as old as age 6, a signal relevant to future IBD risk.

FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer

The FDA approved daraxonrasib (Rasonque), a first-in-class RAS(ON) multi-selective inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.

In the phase 3 RASolute 302 trial, daraxonrasib produced a median overall survival of 13.2 months compared with 6.7 months with chemotherapy.

That's a roughly 60% reduction in the risk of death. Common side effects included rash, diarrhea, and fatigue.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD

ABTECT Part 2 Data: Obefazimod Sustains Remission in UC

Remo Panaccione, MD, of the University of Calgary discussed phase 3 ABTECT maintenance data for obefazimod in moderate-to-severe ulcerative colitis.

At week 44, both the 25 mg and 50 mg doses achieved clinical remission in about 51% of patients, compared with 10% on placebo. That included patients who had not initially responded to induction.

Endoscopic remission reached 41.5% and 47.7% with the two doses, respectively. Panaccione said no new safety signals emerged across more than 1,700 patient-years of exposure.

Abivax plans to submit an NDA in the fourth quarter of 2026.

43% Lower Mortality Seen in Colorectal Screening Participants

Johannes Blom, MD, PhD, of the Karolinska Institute discussed a reanalysis of Sweden's Stockholm-Gotland fecal occult blood test screening program that corrected for contamination bias and nonadherence.

Invitation to screening was associated with a 26% reduction in colorectal cancer mortality, up from an original 14% estimate.

Actual participation in screening was associated with a 43% reduction.

Sugar-Sweetened Beverages Associated With Increased Gastric Cancer Risk, With Andrew Chan, MD, MPH

Andrew Chan, MD, MPH, of Massachusetts General Hospital discussed a 2-decade cohort study of 112,284 participants published in Gastro Hep Advances.

Daily intake of more than one sugar-sweetened beverage was associated with substantially higher gastric cancer incidence compared with never consuming them. Artificially sweetened beverages showed no similar link.

Chan said the finding points to a possible connection between metabolic dysfunction and gastric cancer risk that hasn't been well characterized before.

"Forever Chemicals" Are in Cord Blood And Tied to Gut Inflammation in Kids

Elizabeth Spencer, MD, of the Icahn School of Medicine at Mount Sinai discussed a new analysis linking early-life exposure to PFAS, or "forever chemicals," to elevated fecal calprotectin, a marker of intestinal inflammation, in children up to age 6 across three birth cohorts.

Mothers with IBD had higher levels of the same PFAS metabolites most linked to their children's elevated calprotectin.

Spencer noted that none of the children studied have been diagnosed with IBD, and cautioned the findings represent an association rather than a proven causal pathway.

Articles

FDA activity, trial readouts, and epidemiologic reanalyses signaled meaningful shifts across GI oncology, IBD therapeutics, and prevention. Daraxonrasib, a first-in-class oral RAS(ON) multi-selective inhibitor, gained approval for previously treated metastatic pancreatic adenocarcinoma on a phase 3 overall-survival advantage. In moderate-to-severe ulcerative colitis, obefazimod maintenance data demonstrated durable clinical and endoscopic remission without new safety signals and supports a planned 2026 NDA. Screening program reanalysis suggested substantially greater colorectal cancer mortality benefit when accounting for contamination and nonadherence. Cohort data linked sugar-sweetened beverages—but not artificially sweetened—to gastric cancer risk. Prenatal PFAS exposure correlated with higher pediatric fecal calprotectin.

Gastroenterology in September 2026: RAS inhibitor approval for pancreatic cancer, ABTECT UC data, CRC screening mortality, and GI cancer risk.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

6 Gastroenterology Headlines You Missed in August 2026

 news this month centered on regulatory developments in cholestatic and viral liver disease, along with new data on diet-driven liver fat reduction and alcohol use disorder treatment in patients with chronic liver disease. 

 granted volixibat Breakthrough Therapy and Orphan Drug designations for cholestatic pruritus due to 

, based on phase 2b VISTAS trial results, although the agency has since recommended an additional phase 3 study before Mirum Pharmaceuticals submits a new drug application (NDA). Separately, the FDA accepted an NDA for lonafarnib in chronic hepatitis D (CHD) on August 11, 2026, backed primarily by phase 3 D-LIVR trial data, positioning the oral agent as a potential first-in-class option for a condition with no currently approved oral therapy in the United States. 

On the diet and metabolic front, a randomized trial published August 27, 2026, in Cell Metabolism found that a ketogenic diet reduced liver fat and improved glycemic control more than Mediterranean or plant-forward diets, even after matched weight loss. 

In an interview with HCPLive, Mandana Khalili, MD, of UCSF and Zuckerberg San Francisco General Hospital, discussed findings from a randomized trial showing that patients' baseline motivation and confidence predicted their success in reducing alcohol use as part of a telehealth-delivered stepped alcohol treatment model for chronic liver disease.

FDA Grants Volixibat Breakthrough Therapy, Orphan Designations for PSC

The FDA granted volixibat, an investigational ileal bile acid transporter inhibitor, Breakthrough Therapy and Orphan Drug designations on August 5, 2026, for cholestatic pruritus due to PSC, an area without any disease-specific symptomatic therapies. The designations were based on topline results from the phase 2b VISTAS trial, in which volixibat produced a statistically significant, placebo-adjusted improvement in itch severity along with reduced serum bile acids. At a subsequent pre-NDA meeting, the FDA recommended that Mirum Pharmaceuticals conduct an additional phase 3 study before submission, pushing a potential NDA filing to the first half of 2027.

Lonafarnib NDA Enters FDA Review for Chronic Hepatitis D

The FDA accepted EIT Pharma's NDA for lonafarnib as a treatment for chronic hepatitis D on August 11, 2026, supported primarily by the phase 3 D-LIVR trial, which enrolled more than 400 patients across 21 countries. Lonafarnib, an oral agent designed to interfere with the hepatitis D virus life cycle, previously received FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations. No FDA action date, advisory committee plans, or proposed regimen have been disclosed.

Ketogenic Diet Offers Liver Benefits Beyond Weight Loss Alone

A randomized trial published August 27, 2026, in Cell Metabolism compared ketogenic, Mediterranean, and very-low-fat plant-forward diets in 55 adults with obesity, prediabetes, and hepatic steatosis. After matched weight loss of roughly 10% across all three groups, the ketogenic diet produced a 67% reduction in intrahepatic triglyceride content, compared with 45% in the other two groups, along with greater improvements in hepatic insulin sensitivity and glycemic measures. Half of participants in the ketogenic group had remission of prediabetes, versus 29% in the Mediterranean group and 7% in the plant-forward group.

Baseline Motivation Predicts Alcohol Reduction in Chronic Liver Disease

Mandana Khalili, MD, of UCSF and Zuckerberg San Francisco General Hospital, discussed findings from a randomized controlled trial of a telehealth-delivered stepped alcohol treatment (SAT) model in patients with chronic liver disease and unhealthy alcohol use. Higher baseline confidence predicted a 43% increase in the odds of achieving less-than-moderate alcohol use, while higher baseline importance predicted a 40% increase in the odds of 30-day abstinence at 6 months. Khalili noted that motivational interviewing can be taught to hepatologists, making the model potentially replicable even in clinics without dedicated behavioral health staff.

Hepatology developments highlighted late-stage regulatory activity in cholestatic and viral liver diseases, alongside mechanistic clinical data in metabolic liver disease and alcohol use interventions. Volixibat received FDA Breakthrough Therapy and Orphan Drug designations for PSC-associated cholestatic pruritus after phase 2b improvements in itch and serum bile acids, though an additional phase 3 study was requested before NDA submission. The FDA also accepted an NDA for lonafarnib in chronic hepatitis D. A randomized diet trial showed ketogenic eating reduced liver fat and improved glycemic endpoints beyond weight loss, while telehealth stepped alcohol treatment outcomes correlated with baseline motivation metrics.

Hepatology in September 2026: FDA designations for volixibat and lonafarnib, ketogenic diet liver data, and alcohol use in CLD.

Hepatology

Videos

5 Hepatology Headlines You Missed in August 2026

Radhika Shah, MD, serves as a board-certified dermatologist for the Schweiger Dermatology Group.

Chronic hand eczema (CHE) often involves overlapping immunologic pathways beyond classic atopic dermatitis, requiring broader diagnostic consideration of irritant and allergic contact dermatitis.

Quality-of-life impact, including pain, itching, sleep disturbance, and visible appearance, plays a central role in how Radhika Shah, MD, assesses CHE severity.

Traditional topical therapies carry meaningful limitations, and Shah said clinicians should not hesitate to consider systemic or biologic therapy even when hand involvement represents a small body surface area.

 is increasingly recognized as a distinct disease entity rather than a simple extension of atopic dermatitis, according to Radhika Shah, MD, a board-certified dermatologist at Schweiger Dermatology Group who specializes in medical, surgical, and cosmetic dermatology.

, Shah, who combines a background in pharmacy with dermatology to develop individualized treatment plans, explained why this distinction meaningfully changes how clinicians should diagnose and manage the condition. She spoke with the editorial team in this interview as a recap of her recent clinical forum, ‘Chronic Hand Eczema: Advancing Care Across the Treatment Continuum.’

Chronic Hand Eczema: A Clinical Forum Recap, With Radhika Shah, MD

Why Does CHE Deserve Its Own Diagnostic Framework?

Shah said the hands warrant special consideration given how frequently they are exposed to irritants, particularly amid increased hand sanitizer and handwashing use since the COVID-19 pandemic. This frequent exposure can introduce irritant contact dermatitis alongside underlying atopic dermatitis, engaging additional immunologic pathways, including Th1 and Th17 activity, beyond the traditional Th2 and Th22 pathways associated with classic atopic dermatitis. Shah noted patients treated only for atopic dermatitis of the hands, such as nurses or nail technicians with frequent chemical or water exposure, may be undertreated if clinicians target only a single immunologic pathway rather than accounting for this broader immune involvement.

What Makes CHE Difficult to Diagnose and Manage?

Shah said the central diagnostic challenge involves distinguishing between contact dermatitis, atopic dermatitis, and mixed presentations. She noted patients typically present with redness, fissuring, and scaling, requiring clinicians to piece together occupational exposures, hobbies, and potential allergens contributing to the presentation. Once a mixed picture is identified, Shah said treatment often needs to be broadened accordingly.

How Should Clinicians Weigh Quality of Life in Severity Assessment?

According to Shah, quality-of-life impact, including pain, itching, sleep disturbance, and the visible appearance of the hands, is often the most important factor in her severity assessments, sometimes outweighing objective disease severity. She noted patients place significant weight on hand appearance given how visible and functionally essential hands are in daily life and public interaction. For structured severity scoring, Shah said she uses the Investigator Global Assessment scale developed by LEO Pharma during the Anzupgo studies, which ranges from 0, indicating clear skin, to 4, indicating severe disease.

What Are the Limitations of Traditional Topical Therapies?

Shah said she generally avoids calcineurin inhibitors in her practice due to a burning sensation that reduces patient compliance, often resulting in disease flares when patients stop using prescribed treatment. While she considers topical corticosteroids highly effective, Shah noted she has observed fissuring between the fingers, dorsal hand atrophy, and dyspigmentation with prolonged high-potency steroid use, particularly among patients with skin of color who may already have pigmentary changes from chronic inflammation. She characterized topical corticosteroids as effective bridge therapy rather than a long-term solution, given the chronic, incurable nature of CHE.

How Does Shah Approach the Decision to Move to Systemic Therapy?

For patients refractory to topical treatment, Shah said the decision to pursue systemic or biologic therapy depends heavily on patient comfort and clinical history, including flare frequency, family history of eczema, and involvement of other body areas. Patients with an atopic dermatitis background are often considered for injectable biologic therapy, while those with suspected allergic contact dermatitis are referred for patch testing.

Shah described a case involving a nail technician with an acrylate allergy who could not change occupations, for whom an oral JAK inhibitor combined with other therapies achieved disease stability. For patients hesitant about long-term systemic therapy, Shah said a short prednisone course may be considered, with the caveat that repeated courses should prompt reconsideration of systemic treatment.

What Should Clinicians Change About Their Approach to CHE?

Shah's top recommendation for clinicians is to more consistently consider irritant contact dermatitis as a contributing factor rather than defaulting to atopic dermatitis or psoriasis when evaluating hand scaling, particularly in the post-COVID era. She encouraged greater clinician comfort with topical and systemic JAK inhibitors when clinically warranted. Shah also emphasized that hand-limited disease should not be viewed as lower priority simply because it represents a smaller body surface area, noting the substantial quality-of-life and compliance benefits systemic therapy can offer patients who struggle with long-term topical adherence.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools. Shah had no relevant disclosures of note.

Ghezzi G, Falcidia C, Valenti M, et al. Chronic Hand Eczema (CHE): A Narrative Review. Dermatol Ther (Heidelb). 2025 Apr;15(4):771-795. doi: 10.1007/s13555-025-01365-7. Epub 2025 Mar 10. PMID: 40064754; PMCID: PMC11971080.

Chronic Hand Eczema: Advancing Care Across the Treatment Continuum. HCPLive Clinical Forum. August 18, 2026. 

https://registration.hcplive.com/clinical-forum-8-18-26

Radhika Shah, MD, explains why chronic hand eczema requires distinct diagnosis and treatment strategies, from topical limits to systemic therapy.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Stephen Greene, MD, is an associate professor of medicine at Duke University School of Medicine and cardiologist at the Duke Clinical Research Institute in Durham, NC. Greene is a member of HCPLive's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Muthiah Vaduganathan, MD, MPH, is a cardiologist specializing in cardiorenal metabolism at Brigham and Women's Hospital in Boston, MA. Vaduganathan is a member of Practical Cardiology's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Stephen Greene, MD, an advanced heart failure specialist at Duke University School of Medicine, and Muthiah Vaduganathan, MD, MPH, a cardiologist at Brigham and Women's Hospital, recorded this episode on site at the 

2026 European Society of Cardiology (ESC) Congress

 in Munich, Germany. The hosts walk through the headline neutral result of CARDIO-TTRansform, the largest transthyretin amyloid cardiomyopathy (ATTR-CM) trial to date, and the major structural changes in the newly released 2026 ESC 

Don't Miss a Beat: CARDIO-TTRansform and New HF Guidelines at ESC 2026

CARDIO-TTRansform: Eplontersen Misses Its Primary Endpoint in ATTR-CM

Vaduganathan opens by noting Hotline Session 1 shifted focus toward specific cardiomyopathies, including CARDIO-TTRansform, which tested eplontersen, a transthyretin gene silencer, against placebo in more than 1400 patients with ATTR-CM across 20 countries.¹ Greene frames the trial against the three approved disease-modifying ATTR-CM therapies to date: TTR stabilizers tafamidis and acoramidis, and vutrisiran, another silencer meeting its primary endpoint in HELIOS-B. 

For the composite primary endpoint of cardiovascular death or recurrent cardiovascular events, CARDIO-TTRansform was neutral, with a rate ratio of 0.89. Greene highlights a detail he found notable despite the neutral topline: all-cause mortality showed a nominally significant 20% relative risk reduction, echoing a pattern the hosts previously discussed with the VICTOR trial.

Background Stabilizer Use Complicates the Combination Therapy Question

Vaduganathan explains why background TTR stabilizer therapy is central to interpreting the results. Unlike HELIOS-B, where stabilizer use was modest at baseline, 57% of CARDIO-TTRansform participants were already on a stabilizer at enrollment. Another 24% started one during follow-up, leaving roughly 80% exposed to stabilizer therapy at some point in the trial. 

A prespecified subgroup analysis suggested benefit with eplontersen monotherapy but no apparent effect among patients already on a stabilizer. Vaduganathan points to a meta-analysis of CARDIO-TTRansform and HELIOS-B published alongside the trial in JAMA, finding clinical benefit concentrated in patients not previously treated with a stabilizer.² 

A similar signal appeared in 6-minute walk distance and Kansas City Cardiomyopathy Questionnaire scores. Greene calls the finding hypothesis-generating rather than definitive, noting the central open question in ATTR-CM is now whether and when to combine mechanisms rather than assuming additive benefit by default.

The 2026 ESC Heart Failure Guidelines Replace GDMT With FMT and AMT

Turning to the newly released 2026 ESC heart failure guidelines, Greene highlights 2 structural changes. First, the guidelines adopt the Universal Definition of Heart Failure's 2-category approach, eliminating heart failure with mildly reduced ejection fraction and defining HFrEF as an ejection fraction below 50%. Second, the familiar term guideline-directed medical therapy is replaced with foundational medical therapy (FMT), tracking with class I recommendations, alongside additional medical therapies (AMT) and a new guideline-directed interventional therapy (GDIT) category for procedures.³

A New Two-Pillar Approach for HFpEF, With Some Loss of Nuance

Vaduganathan explains FMT now includes SGLT2 inhibitors and mineralocorticoid receptor antagonists (MRAs) for all patients with heart failure regardless of ejection fraction. ACE inhibitors, angiotensin receptor-neprilysin inhibitors or angiotensin receptor blockers, and beta-blockers are added for HFrEF. 

Greene welcomes explicit guideline text discouraging overthinking sequencing, alongside a new class I recommendation for in-hospital initiation of SGLT2 inhibitors. Vaduganathan cautions the simplified 2-pillar framework introduces some loss of nuance at the drug level. 

The guidelines recommend steroidal MRAs in HFrEF but permit either steroidal or nonsteroidal MRAs in HFpEF, a designation Vaduganathan calls imperfectly aligned with the trial evidence. FINEARTS-HF enrolled patients with an ejection fraction of 40% or higher, and spironolactone now carries a class I recommendation in HFpEF despite never being studied in this population in TOPCAT. Greene adds clinicians still need to know a patient's exact ejection fraction, since decisions about AMTs and devices continue to depend on it. 

The hosts close by noting the new ESC cardiovascular disease and chronic kidney disease guideline, released the same day, recommends MRA use in a way diverging from the heart failure guideline. Vaduganathan's point: guidelines require clinical judgment grounded in the underlying trial evidence, not uncritical adoption.

Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others.

Fontana M, Masri A, Solomon SD, et al; CARDIO-TTRansform Investigators. Eplontersen for transthyretin amyloid cardiomyopathy. 

. Published online August 28, 2026. doi:10.1056/NEJMoa2608510

Gillmore JD, Hamatani Y, Fontana M, et al. Gene silencer therapy in transthyretin amyloid cardiomyopathy: a meta-analysis of outcomes trials. 

. Published online August 30, 2026. doi:10.1001/jama.2026.17246

Køber L, Adamo M, Ruwald A, et al. 2026 ESC Guidelines for the management of heart failure. 

. 2026;ehag100. doi:10.1093/eurheartj/ehag100

Podcasts

Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, break down CARDIO-TTRansform and the new 2026 ESC heart failure guidelines.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Don’t Miss a Beat

The Don't Miss a Beat podcast breaks down the latest evidence and clinical trial insights across cardiovascular, renal, and metabolic diseases. Don’t Miss a Beat as Steve Greene, MD, and Muthu Vaduganathan, MD, MPH, critically examine recent advances in clinical care and research with perspectives from global experts in the field.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

August brought a wave of movement across 

, from a new cardiovascular indication for one of the field’s top-selling therapies, tirzepatide, to the first device capable of tracking ketones and glucose together. On the trial-data side, avexitide displayed strong phase 3 results in a condition with no approved therapies (post-bariatric hypoglycemia), and this month’s 

 podcast explored topline retatrutide data alongside a sobering look at online GLP-1 prescribing practices.

Below is a roundup of 4 of the month's biggest endocrinology stories. The podcast episode covered here is one of 6 

New FDA Approvals and Authorizations in Diabetes Care

Tirzepatide Gets FDA Approval to Cut Cardiovascular Risk in Type 2 Diabetes

The US Food & Drug Administration (FDA) has approved tirzepatide (Mounjaro) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk, based on results from the SURPASS-CVOT trial. The phase 3, event-driven trial enrolled > 13,000 participants and compared tirzepatide against dulaglutide (Trulicity) rather than placebo. This marked the first head-to-head cardiovascular outcomes comparison between 2 incretin therapies.

Over a median follow-up of about 4 years, tirzepatide met its non-inferiority objective for MACE-3, showing an 8% lower event rate than dulaglutide, though superiority was not established. The safety profile remained consistent with tirzepatide's existing label, with no new signals identified.

Libre Duo 10 Day Authorized as First Glucose-Ketone Monitor for Diabetes

The FDA has granted De Novo marketing authorization to Abbott's Libre Duo 10 Day, the first continuous sensor worldwide to track both glucose and ketone levels in a single wearable. Authorized for patients aged ≥ 2 years with diabetes, the device measures both analytes in interstitial fluid every minute across a 10-day wear period, sending real-time readings to a smartphone and issuing alerts when ketone levels cross a risk threshold. The authorization was based on 6 clinical studies enrolling more than 600 participants and followed a Breakthrough Device designation. By pairing continuous ketone surveillance with glucose data for the first time, the device aims to help flag rising ketones before diabetic ketoacidosis develops.

Phase 3 Data and Pipeline Updates in Metabolic Disease

Avexitide Reduces Hypoglycemic Events in Phase 3 LUCIDITY Trial for PBH

Amylyx Pharmaceuticals reported positive topline results from the phase 3 LUCIDITY trial of avexitide, an investigational GLP-1 receptor antagonist, in adults with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass. The 78-participant trial met its FDA-agreed primary endpoint, with avexitide reducing composite Level 2 and Level 3 hypoglycemic events by 55% versus placebo (

 =.000003) over 16 weeks, and it met all secondary endpoints as well. Amylyx plans to submit a new drug application (NDA) by the end of 2026, with a potential launch in 2027 if approved.

Podcast Roundup: Diabetes Dialogue's August GLP-1 Coverage

Diabetes Dialogue: Retatrutide Phase 3 Data Show Major Weight Loss

, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, break down topline phase 3 results for retatrutide, a GLP-1/GIP/glucagon triple receptor agonist. In TRIUMPH-2, the 12 mg dose produced roughly 21% weight loss and an A1C reduction of 1.4-1.6 percentage points from a 7.7% baseline. In TRIUMPH-3, the 12 mg dose delivered 23% weight loss versus 3% with placebo, alongside improvements in triglycerides, non-HDL cholesterol, and systolic blood pressure. The hosts also discuss a JAMA secret-shopper study finding that 92% of telehealth sites tested prescribed a requested GLP-1 medication, often with minimal verification, raising questions about oversight in online prescribing.

Tech, Screening, and Care Highlights from ADCES 2026

Weekly Insulin Icodec Now Available for Type 2 Diabetes

Ultra-Rapid Insulin, IcoSema Advance in Type 2 Diabetes

FreeStyle Libre Duo Cleared for Ketone Monitoring

Non-Invasive EEG Sensor Aims to Track Glucose in Real Time

Secret Shopper Study Reveals GLP-1 Telehealth Gaps

New approval for tirzepatide, phase 3 wins for avexitide and retatrutide, and a GLP-1 telehealth safety gap in August's biggest endocrinology stories.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 1 Diabetes

Type 2 Diabetes

4 Endocrinology Headlines You Missed in August 2026

David T. Rubin, MD is a professor of medicine at the University of Chicago, director of the Inflammatory Bowel Disease Center, and chair of the International Organization for the Study of IBD (IOIBD).

David T. Rubin, MD, on the questions, screening tools, and system barriers standing between IBD care and the whole patient.

Individualizing IBD Care Beyond the Bowel, With David T. Rubin, MD

Owen Muir, MD, DFAACAP, FCTMSS, co-founder and chief medical officer at Radial.

Owen Muir, MD, calls accelerated SWIFT Deep TMS his personal first-line approach for active suicidal ideation, not an established guideline.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Accelerated Deep TMS for Acute Suicidality, With Owen Muir, MD

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

PAH specialists discuss sotatercept, risk-based escalation, and access barriers shaping pulmonary arterial hypertension care.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

How is PAH Treatment and Management Changing? 

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Ixekizumab-Tirzepatide Sustains 1-Year Gains in Psoriatic Disease, Obesity

The FDA is expected to complete its review by late April 2027, based on positive phase 3 results from the TETON-1 and TETON-2 trials in IPF.

Pulmonary Fibrosis

FDA Accepts Nebulized Treprostinil sNDA for Idiopathic Pulmonary Fibrosis

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The ASPIRED trial found immediate ECG monitoring in the ED did not reduce recurrent syncope but doubled arrhythmia detection and cut mortality.

Immediate ECG Monitoring Cuts Mortality in Unexplained Syncope

A secondary analysis found the SWIFT accelerated protocol eased suicidal ideation faster than standard daily deep TMS dosing in major depressive disorder.

Deep TMS Reduces Suicidal Ideation by 70% in MDD, With Owen Muir, MD

A gastroenterologist explains why treating bowel inflammation alone isn't enough to call inflammatory bowel disease "controlled."

What Comprehensive Disease Control Means for IBD, With David Rubin, MD

The phase 2a study found TEV '408 significantly reduced intestinal damage and inflammation versus placebo at week 8

TEV '408 Meets Primary Endpoint in Celiac Trial

The HCPLive editorial team previews late-breaking abstracts across COPD, asthma, IPF, PAH, and AATD ahead of ERS Congress 2026 in Barcelona.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Latest News

6 Gastroenterology Headlines You Missed in August 2026

5 Hepatology Headlines You Missed in August 2026

Chronic Hand Eczema: A Clinical Forum Recap, With Radhika Shah, MD

Don't Miss a Beat: CARDIO-TTRansform and New HF Guidelines at ESC 2026

4 Endocrinology Headlines You Missed in August 2026